TAVR, or transcatheter aortic valve replacement, is a minimally invasive heart procedure that replaces a diseased aortic valve without open-heart surgery. Instead of opening the chest and stopping the heart, a cardiologist threads a new valve through a blood vessel, typically in the groin, and positions it inside the old valve. The procedure takes about an hour, and most patients go home the same day or the next morning.
Why TAVR Is Performed
TAVR treats aortic stenosis, a condition where the aortic valve narrows and stiffens over time, forcing the heart to work harder to push blood out to the body. A healthy aortic valve opening measures 3 to 4 square centimeters. When that opening shrinks below 1 square centimeter, stenosis is classified as severe, and symptoms like chest pain, shortness of breath, fainting, and fatigue typically follow. Left untreated, severe aortic stenosis carries a high risk of heart failure and death within a few years of symptom onset.
Not everyone with aortic stenosis needs TAVR. The procedure becomes an option once stenosis reaches the severe stage and symptoms appear or heart function starts to decline. Your care team uses echocardiography to measure the valve opening, the pressure difference across the valve, and the speed of blood flow through the narrowed area to determine severity.
Who Is a Candidate
Current American guidelines recommend TAVR for patients over 80 or those with a life expectancy under 10 years. European guidelines set the threshold slightly lower, at age 75, or for patients with elevated surgical risk scores. Patients younger than 65 with a life expectancy over 20 years are generally directed toward traditional open-heart surgery (called SAVR), partly because the long-term durability data for TAVR valves is still maturing. For patients between these age ranges, the decision often comes down to individual anatomy, overall health, and discussion with a heart team.
How the Procedure Works
Before the procedure, your team orders a detailed CT scan of your heart, aorta, and the blood vessels in your legs and abdomen. This scan produces three-dimensional measurements of your aortic valve ring, the distance to your coronary arteries, and the angle of your aortic root. These measurements determine which valve size fits and how the delivery system will navigate to the right position. You may also have an echocardiogram and, in some cases, a cardiac catheterization.
On procedure day, the most common approach is transfemoral, meaning the catheter enters through a large artery in the groin. A thin, flexible delivery system carrying the compressed replacement valve is guided up through the aorta using real-time X-ray imaging (fluoroscopy). Once the new valve reaches the diseased native valve, it is expanded into place, pushing the old valve leaflets aside.
Two main valve designs exist. Balloon-expandable valves are inflated with a small balloon once positioned. During that brief inflation, the heart is paced at a very rapid rate to temporarily reduce blood flow so the valve doesn’t shift. Self-expanding valves are made of a shape-memory metal that springs open on its own once released from its delivery sheath, requiring less aggressive pacing. After deployment, the team uses imaging to check that the valve is seated properly, blood is flowing correctly, and there are no significant leaks around the edges.
Alternative Access Routes
Femoral access through the groin is the standard, but some patients have blood vessels that are too narrow, too calcified, or too tortuous for the catheter to pass safely. In those cases, the valve can be delivered through an artery under the collarbone (subclavian or axillary access), through the neck’s carotid artery, or directly through a small chest incision into the aorta. These alternative routes involve slightly longer recovery times and, in some studies, a modestly higher rate of pacemaker implantation afterward.
TAVR Compared to Open-Heart Surgery
In a large meta-analysis comparing TAVR to traditional surgical valve replacement, TAVR patients had lower 30-day mortality (2.5% vs. 3.0%), lower stroke rates (3.2% vs. 4.1%), and substantially less major bleeding (11.3% vs. 31%). At one year, mortality rates between the two approaches are similar for intermediate-risk patients. The key advantage of TAVR is the less traumatic recovery: no chest bone splitting, no heart-lung bypass machine, and a hospital stay measured in hours rather than days.
The tradeoff is that TAVR carries a higher rate of certain complications, particularly the need for a permanent pacemaker and minor leaking around the new valve. Open-heart surgery remains preferred for younger patients who need a valve that will last decades and for those with anatomy that doesn’t suit a catheter-based approach.
Risks and Complications
The most common complication after TAVR is the need for a permanent pacemaker. The new valve sits right next to the heart’s electrical wiring, and expanding it can disrupt the signals that keep the heart beating in rhythm. Overall, about 10 to 11% of TAVR patients require a pacemaker, though rates vary by valve type. Balloon-expandable valves carry a pacemaker rate of roughly 10%, while self-expanding valves run closer to 18%. These rates have been slowly improving with newer techniques but remain higher than with open-heart surgery.
Another issue to watch for is a new electrical conduction problem called left bundle branch block, which occurs in 10 to 30% of patients. Most people with this issue do not ultimately need a pacemaker, but about 10 to 15% of them will require one within the first year. Other possible complications include stroke, bleeding at the access site, kidney injury from contrast dye, and small leaks around the valve (paravalvular leak), though significant leaks have become less common with newer valve designs.
Recovery Timeline
Recovery depends on how the valve was delivered. With the standard groin approach, many patients go home within 24 hours. You should avoid lifting anything over 10 pounds and skip strenuous activities for the first five to seven days. Most people return to their normal routine within a week, gradually increasing activity each day. Stairs are fine right away, just take them slowly.
If the valve was placed through a chest incision (transapical or transaortic approach), the hospital stay stretches to several days, and the lifting restriction extends to eight weeks. You won’t be cleared to drive until your doctor confirms your sternum or incision site has healed adequately. Walking daily is encouraged from the start, with gradual increases in distance and effort.
Medications After the Procedure
After TAVR, you will take blood-thinning or antiplatelet medications to prevent clots from forming on the new valve. The typical regimen for patients who don’t already take a blood thinner is a single antiplatelet drug (like aspirin or clopidogrel) for the first three to six months, sometimes two antiplatelet drugs if bleeding risk is low. After that initial period, you continue on one antiplatelet medication long-term. If you develop an irregular heart rhythm like atrial fibrillation after the procedure, or if imaging shows early clot formation on the valve leaflets, your doctor will add an anticoagulant.
How Long TAVR Valves Last
Durability has been one of the biggest questions surrounding TAVR, especially as the procedure expands to younger patients. The longest follow-up data now extends beyond 10 years. In a study tracking high-risk patients, signs of valve deterioration appeared in about 4.8% of patients at 9 years and 6.4% at 10 years. By 12 years, that figure rose to roughly 9.8%. Only a small fraction of these cases were severe enough to require re-intervention.
Among patients with echocardiographic follow-up past nine years, severe valve deterioration occurred in just 3.6%, while moderate deterioration was seen in 5.4%. Self-expanding valves appeared to hold up better than balloon-expandable valves in this long-term analysis, with deterioration rates of 2.8% versus 20% in the extended follow-up group. These numbers are encouraging, though they come from early-generation devices implanted in older, higher-risk patients. Whether newer valves placed in younger, healthier patients will perform as well or better over 15 to 20 years remains an open question that ongoing studies are tracking.